• 18 OCT 06
    • 0

    Dr. Jeffrey Bibbs, CEO of Pharmatek, to Speak at BioScience Forum October 18, 2006

    SAN DIEGO, Calif. – October 18, 2006 – Pharmatek Laboratories – a premier pharmaceutical chemistry development organization supporting the pharmaceutical industry – today announced that its chief executive officer and chief scientific officer Jeffrey A. Bibbs will speak at the October 18, 2006 BioScience Forum at the Clarion Hotel, Millbrae, California.

    Bibbs’ presentation, titled “Strategies for Rapid Development of Pharmaceutical Formulations,” will describe approaches for streamlining formulation development of small molecule drug candidates. Using case studies, he will present formulation strategies for several therapeutic areas, including rheumatoid arthritis, obesity, and cancer. Bibbs will discuss formulation support issues, such as analytical methods and key preformulation studies, and how these aspects influence formulation development. Considerations for physiochemical characteristics will be discussed, as well as other important factors, such as mode of administration and manufacturing. A recognized expert in drug development with more than fifteen years experience, Bibbs has worked as a pharmaceutical chemist in academia, pharmaceutical companies and contract research organizations. His background includes preclinical drug development, medicinal chemistry and physical organic chemistry. Under Bibbs’ direction as CSO, Pharmatek has been involved with over 100 IND applications.

    Bibbs worked in medicinal chemistry and drug development for over seven years at Amylin Pharmaceuticals prior to founding Pharmatek. He is an instructor at University of California, San Diego Extension, teaching classes in drug development and formulation development. Bibbs is a co-founder of Diakron Pharmaceuticals, a pharmaceutical company focused on cardiovascular disease. He earned his Ph.D. from the University of Kansas and was a postdoctoral fellow at Texas A&M and The Scripps Research Institute.

    Leave a reply →